Immuron(US:IMRN) Accessnewswire·2026-03-05 16:05Core Viewpoint - Emerging Growth Research maintains a Buy-Extended rating and a 12-month price target of $3.90 for Immuron Limited following the release of its first-half fiscal year 2026 financial results and strategic update [1] Financial Performance - Immuron reported global product revenue of AUD $4.18 million for the six months ended December 31, 2025, reflecting approximately 5% growth year-over-year [1] - Australian revenue increased by 13% year-over-year, while U.S. revenue rose by 17%. Canadian revenue declined due to distributor-level dynamics [1] - Gross margin for the first half was 63.4%, and the operating margin improved due to lower general and administrative and research and development expenses [1] - Net loss narrowed to AUD $(1.92) million compared to AUD $(2.49) million in the prior-year period [1] Capital Position - Immuron raised approximately AUD $7.3 million through its at-the-market facility, increasing its cash balance to approximately AUD $10.0 million as of December 31, 2025 [1] - This capital position is expected to provide operational runway into 2027 [1] Product Development - The December 2025 launch of ProIBS® in Australia contributed initial revenue, with expanded distribution expected to support incremental revenue growth over time [1] - Immuron's clinical-stage pipeline includes IMM-529, which received U.S. FDA authorization to proceed into a randomized, placebo-controlled Phase 2 trial in Australia [1] - The company is seeking development partners for both IMM-529 and IMM-124E to advance clinical development [1] Rating Justification - The maintained Buy-Extended rating reflects the combination of commercial revenue, a strengthened balance sheet, and longer-term clinical development potential, balanced against funding requirements and typical biotechnology development risks [1] - The $3.90 price target is based on a peer-group EV/Revenue valuation methodology applied to Immuron's trailing twelve-month revenue [1]